Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Inclusion Criteria: * Histologically confirmed anaplastic large cell lymphoma * CD30-positive disease * Must be in first or second relapse * Measurable disease * No CNS disease * Karnofsky performance status (PS) 60-100% (\> 16 years of age) OR Lansky PS 60-100% (≤ 16 years of age) * Absolute neutrophil count ≥ 1,000/mm³ * Platelet count ≥ 100,000/mm³ (transfusion independent) * Platelet count ≥ 20,000/mm³ if bone marrow involvement (platelet transfusions allowed) * Hemoglobin ≥ 8.0 g/dL (RBC transfusion independent, unless bone marrow involvement) * Creatinine adjusted according to age as follows: * No greater than 0.4 mg/dL (≤ 5 months) * No greater than 0.5 mg/dL (6 months-11 months) * No greater than 0.6 mg/dL (1 year-23 months) * No greater than 0.8 mg/dL (2 years-5 years) * No greater than 1.0 mg/dL (6 years-9 years) * No greater than 1.2 mg/dL (10 years-12 years) * No greater than 1.4 mg/dL (13 years and over \[female\]) * No greater than 1.5 mg/dL (13 years to 15 years \[male\]) * No greater than 1.7 mg/dL (16 years and over \[male\]) * Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT \< 3 times ULN * Albumin ≥ 2 g/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment * No evidence of graft-vs-host disease * No documented active infection requiring antibiotics * No isolated bone recurrence * Recovered from prior therapy * At least 3 months since prior monoclonal antibody therapy * At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) * At least 7 days since prior hematopoietic growth factor therapy * At least 3 months since prior biologic (antineoplastic) agents * At least 2 weeks since prior local palliative radiotherapy (small port) * At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis * At least 6 weeks since other prior substantial bone marrow irradiation * At least 2 months since prior stem cell transplantation or rescue * No prior monoclonal antibody SGN-30 * Concurrent steroids allowed provided dose has been stable or decreasing for the past 7 days * No concurrent immunosuppressive agents * No concurrent dexamethasone as an antiemetic * No other concurrent investigational drug or anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biological therapy